Acquired resistance mechanisms of EGFR-TKI in advanced non-small cell lung cancer

doi:10.3760/cma.j.issn.1673-422X.2015.06.016

Abstract

Abstract: Since the development of molecular biology, the treatment of advanced non-small cell cancer is shifting from traditional chemotherapy into molecular targeted therapy with genotyping as a guide′s help. The most widely used is epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). With the application of EGFRTKIs, the resistances to EGFR inhibitors are paid more and more attention, in recent years. The main mechanisms of acquired resistances are as follows: secondary mutation of the EGFR gene, amplification of c-MET, Her2 and other target genes, histological transformation, activation of the bypass mechanisms, loss of p53, the relief of negative feedback loops, overlap of mechanisms, etc.

Key words: Carcinoma, non-small cell lung, Drug resistance, neoplasm, Molecular targeted therapy

Zheng Yue, Wei Suju. Acquired resistance mechanisms of EGFR-TKI in advanced non-small cell lung cancer[J]. Journal of International Oncology, 2015, 42(6): 458-461.

References

［1］ Chen W, Zheng R, Zhang S, et al. Annual report on status of cancer in China, 2010［J］. Chin J Cancer Res, 2014, 26(1): 48-58. ［2］ Oxnard GR, Arcila ME, Sima CS, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFRmutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation［J］. Clin Cancer Res, 2011, 17(6): 1616-1622. ［3］ Nelson V, Ziehr J, Agulnik M, et al. Afatinib: emerging nextgeneration tyrosine kinase inhibitor for NSCLC［J］. Onco Targets Therapy, 2013, 6: 135-143. ［4］ Janne PA, Ramalingam SS, ChihHsin YJ, et al. Clinical activity of the mutantselective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitorresistant nonsmall cell lung cancer (NSCLC)［J］. J Clin Oncol, 2014, 32 Suppl 15: 8009. ［5］ Sequist LV, JeanCharles S, Gadgeel SM, et al. Firstinhuman evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M)［J］. J Clin Oncol, 2014, 32 Suppl 15: 8010. ［6］ DongWan K, Lee DH, Kang JH, et al. Clinical activity and safety of HM61713, an EGFRmutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs)［J］. J Clin Oncol, 2014, 32 Suppl 15: 8011. ［7］ Turke AB, Zejnullahu K, Wu YL, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC［J］. Cancer Cell, 2010, 17(1): 77-88. ［8］ Thomson S, Petti F, SujkaKwok I, et al. Kinase switching in mesenchymallike nonsmall cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy［J］. Clin Exp Metastasis, 2008, 25(8): 843-854. ［9］ Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged nonsmall cell lung cancer［J］. Clin Cancer Res, 2012, 18(5): 1472-1482. ［10］ Katayama R, Khan TM, Benes C, et al. Therapeutic strategies to overcome crizotinib resistance in nonsmall cell lung cancers harboring the fusion oncogene EML4ALK［J］. Proc Natl Acad Sci USA, 2011, 108(18): 7535-7540. ［11］ Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALKrearranged lung cancers［J］. Sci Transl Med, 2012, 4(120): 120ra17. ［12］ Takezawa K, Pirazzoli V, Arcila ME, et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFRmutant lung cancers that lack the secondsite EGFRT790M mutation［J］. Cancer Discov, 2012, 2(10): 922-933. ［13］ Sequist LV, Waltman BA, DiasSantagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors［J］. Sci Transl Med, 2011, 3(75): 75ra26. ［14］ Byers LA, Diao L, Wang J, et al. An epithelialmesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance［J］. Clin Cancer Res, 2013, 19(1): 279-290. ［15］ VazquezMartin A, Cufi S, OliverasFerraros C, et al. IGF1R/epithelialtomesenchymal transition (EMT) crosstalk suppresses the erlotinibsensitizing effect of EGFR exon 19 deletion mutations［J］. Sci Rep, 2013, 3: 2560. ［16］ Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFRTKI therapy in 155 patients with EGFRmutant lung cancers［J］. Clin Cancer Res, 2013, 19(8): 2240-2247. ［17］ Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling［J］. Science, 2007, 316(5827): 1039-1043. ［18］ Niederst MJ, Engelman JA. Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer［J］. Sci Signal, 2013, 6(294): re6. ［19］ Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer［J］. J Clin Oncol, 2013, 31(31): 3987-3996. ［20］ Chong CR, Janne PA. The quest to overcome resistance to EGFRtargeted therapies in cancer［J］. Nat Med, 2013, 19(11): 1389-1400. ［21］ Guix M, Faber AC, Wang SE, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGFbinding proteins［J］. J Clin Invest, 2008, 118(7): 2609-2619. ［22］ Cortot AB, Repellin CE, Shimamura T, et al. Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway［J］. Cancer Res, 2013, 73(2): 834-843. ［23］ Terai H, Soejima K, Yasuda H, et al. Activation of the FGF2FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC［J］. Mol Cancer Res, 2013, 11(7): 759-767. ［24］ Huang S, Benavente S, Armstrong EA, et al. p53 modulates acquired resistance to EGFR inhibitors and radiation［J］. Cancer Res, 2011, 71(22): 7071-7079. ［25］ Sauer L, Gitenay D, Vo C, et al. Mutant p53 initiates a feedback loop that involves Egr1/EGF receptor/ERK in prostate cancer cells［J］. Oncogene, 2010, 29(18): 2628-2637. ［26］ Zwang Y, SasChen A, Drier Y, et al. Two phases of mitogenic signaling unveil roles for p53 and EGR1 in elimination of inconsistent growth signals［J］. Mol Cell, 2011, 42(4): 524-535. ［27］ Ohashi K, Sequist LV, Arcila ME, et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1［J］. Proc Natl Acad Sci USA, 2012, 109(31): E2127-2133. ［28］ de Bruin EC, Cowell C, Warne PH, et al. Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer［J］. Cancer Discov, 2014, 4(5): 606-619.

[1]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan. Progress of ferroptosis-related mechanisms in osteosarcoma [J]. Journal of International Oncology, 2024, 51(5): 308-311.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	Huang Hui, Ding Jianghua. Advances in targeting FGFR2 for treatment of advanced cholangiocarcinoma [J]. Journal of International Oncology, 2023, 50(9): 569-573.
[5]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[6]	Liu Li, Zhu Siqi, Sun Mengying, He Jingdong. Progress of PARP inhibitors in targeted therapy of small cell lung cancer [J]. Journal of International Oncology, 2023, 50(6): 368-372.
[7]	Liu Bohan, Huang Junxing. Research progress of solute carriers related genes in malignant tumors [J]. Journal of International Oncology, 2023, 50(5): 280-284.
[8]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong. Research progress on targeted therapy of breast cancer with low expression of HER2 [J]. Journal of International Oncology, 2023, 50(4): 236-240.
[9]	Deng Lili, Duan Xingyu, Li Baozhong. Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma [J]. Journal of International Oncology, 2023, 50(12): 751-757.
[10]	Liu Shaoping, Luo Hanchuan, Lin Shuhan, Luo Jiahui. Current status and research progress of interventional and systemic therapy for advanced hepatocellular carcinoma [J]. Journal of International Oncology, 2023, 50(12): 758-762.
[11]	Jiang Shan, Xu Ximing. Recent progresses of targeted therapy and immunotherapy of hepatocellular carcinoma [J]. Journal of International Oncology, 2023, 50(11): 688-695.
[12]	Jiang Shan, Xu Yangtao, Liu Xin, Chen Wenliang, Xu Ximing. Predictive value of baseline peripheral blood inflammatory biomarkers for prognosis in patients with advanced hepatocellular carcinoma treated with immunotherapy combined with targeted therapy [J]. Journal of International Oncology, 2023, 50(10): 600-607.
[13]	Zhang Jingxian, Su Jianfei, Wei Xueqin, Yi Dan, Li Xiaojiang. Treatment status of non-small cell lung cancer with METexon14 skipping mutation [J]. Journal of International Oncology, 2023, 50(1): 37-41.
[14]	Song Jia, Hu Qinyong. Application of TACE combined with molecular targeted therapy and immunotherapy in BCLC B/C hepatocellular carcinoma [J]. Journal of International Oncology, 2022, 49(9): 550-554.
[15]	Zhang Jingxian, Yi Dan, Li Xiaojiang. Application of antibody-drug conjugates in the treatment of non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(5): 296-301.